Take the CURE Magazine Survey

While strolling through the woods, my eyes landed on a woodpecker, whose actions sparked a cancer analogy in my mind.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

A cognitive behavioral therapy for insomnia may help cancer survivors, along with ways to manage insomnia via sleep pressure, an expert told CURE®.